QDPR Antibody

What is QDPR and what role does it play in neurotransmitter synthesis?

QDPR (Quinoid Dihydropteridine Reductase, also known as DHPR) is a 25-26 kDa enzyme belonging to the Short-chain Dehydrogenase/Reductase (SDR) family. It catalyzes the conversion of quinonoid dihydrobiopterin (q-BH2) into tetrahydrobiopterin (BH4), a critical cofactor for neurotransmitter production .

QDPR functions as a nondisulfide-linked homodimer and is widely expressed in various cell types including fibroblasts, neurons, hepatocytes, and lymphocytes. Its primary function lies in regenerating BH4, which is essential for the hydroxylation of tyrosine and tryptophan in the synthesis pathway of serotonin, dopamine, and other neurotransmitters . This makes QDPR an important enzyme in maintaining proper neurological function.

Human QDPR consists of 244 amino acids with an enzymatic region spanning amino acids 9-230. Research has identified four potential isoform variants, including one with a 3-amino acid insertion after Gly218, another showing deletion of amino acids 36-66, a third containing a five-amino acid substitution for amino acids 147-244, and a fourth that utilizes an alternative start site at Met56 .

What applications are QDPR antibodies most commonly used for in research?

QDPR antibodies serve various critical applications in neuroscience, biochemistry, and pharmacological research:

These applications enable researchers to study QDPR expression patterns, localization, and potential alterations in various experimental and pathological conditions . When selecting application-specific antibodies, researchers should prioritize those validated for their particular experimental system and application.

How should Western blot protocols be optimized for reliable QDPR detection?

Optimizing Western blot protocols for QDPR detection requires attention to several key parameters:

• Sample Preparation:

  • Liver tissue samples typically yield strong QDPR signals as the protein is highly expressed in hepatocytes

  • For cell lines, transfected 293T cells have been effectively used as positive controls

  • Use RIPA buffer supplemented with protease inhibitors for efficient protein extraction

• Running Conditions:

  • Use reducing conditions as demonstrated in validated protocols

  • QDPR migrates at approximately 25-30 kDa on SDS-PAGE gels; use Immunoblot Buffer Group 1 for optimal results

• Antibody Dilution and Incubation:

  • Primary antibody dilution typically ranges from 1:500 to 1:2000 depending on the specific antibody

  • For polyclonal antibodies such as 14908-1-AP, a 1:500-1:2000 dilution is recommended

  • For monoclonal antibodies like EP12595, follow manufacturer-specific recommendations

• Detection System:

  • HRP-conjugated secondary antibodies work well for QDPR detection

  • For sheep-derived primary antibodies, use Anti-Sheep IgG Secondary Antibody (e.g., HAF016)

  • For rabbit-derived primary antibodies, corresponding Anti-Rabbit IgG secondaries are appropriate

• Controls:

  • Include mouse or rat liver tissue lysates as positive controls

  • Use GAPDH (36.1 kDa) as a loading control and specificity check

  • RNAi validation can provide confirmation of antibody specificity

Researchers should expect to observe a specific band at approximately 25-30 kDa representing QDPR protein .

What are the recommended approaches for QDPR immunohistochemistry in neural tissues?

For successful immunohistochemical detection of QDPR in neural tissues, researchers should consider the following methodological approach:

• Tissue Preparation:

  • Formalin-fixed, paraffin-embedded (FFPE) sections work well for QDPR detection

  • Fresh frozen sections may provide better antigen preservation for certain applications

• Antigen Retrieval:

  • Heat-induced epitope retrieval (HIER) is essential for optimal staining

  • Primary recommendation: TE buffer at pH 9.0

  • Alternative approach: Citrate buffer at pH 6.0

• Antibody Selection and Dilution:

  • For polyclonal antibodies: Dilution ranges from 1:50 to 1:500 are typically effective

  • For mouse brain tissue, antibodies such as 14908-1-AP have been validated at these concentrations

  • For human hippocampus, antibodies like NBP2-32408 have shown strong cytoplasmic positivity in glial cells at dilutions of 1:1000-1:2500

• Detection Systems:

  • Standard ABC (Avidin-Biotin Complex) or polymer-based detection systems work effectively

  • DAB (3,3'-diaminobenzidine) chromogen produces clear visualization of QDPR expression

• Counterstaining and Analysis:

  • Light hematoxylin counterstaining allows visualization of tissue architecture

  • QDPR typically shows cytoplasmic localization in neural cells

Notably, immunostaining of human hippocampus has revealed strong cytoplasmic positivity for QDPR specifically in glial cells, providing insights into the cell-type specific expression pattern of this enzyme in neural tissues .

How can researchers distinguish between wild-type QDPR and pathological variants in experimental models?

Distinguishing between wild-type QDPR and pathological variants requires specialized approaches combining molecular and immunological techniques:

• Genetic Characterization:

  • Pathologic conditions are associated with single amino acid substitutions at multiple sites, including Gly17, Gly23, Gln66, and His158

  • PCR-based genotyping can identify known mutations

• Antibody Selection Strategies:

  • Most commercial antibodies target conserved regions and cannot directly differentiate variants

  • Custom antibodies raised against peptides containing specific mutation sites may allow direct detection of variants

• Functional Analysis Approach:

  • Combine immunodetection with activity assays to correlate QDPR protein levels with enzymatic function

  • Kinetic assays measuring the rate of BH4 regeneration can identify functionally impaired variants

• Expression System Models:

  • Overexpression systems using 293T cells have been successfully employed to study QDPR variants

  • Analysis comparing QDPR-transfected and non-transfected lysates provides controls for specificity

  • RNAi validation experiments provide additional verification of antibody specificity for variant studies

• Biochemical Characterization:

  • Size-exclusion chromatography can assess whether mutations affect dimerization

  • Circular dichroism spectroscopy can evaluate structural changes in variants

Researchers studying pathological variants should consider combining these approaches, as no single method can comprehensively distinguish all potential variants.

What is known about QDPR subcellular localization and how can it be effectively studied?

QDPR demonstrates distinct subcellular localization patterns that can be effectively studied using various immunological approaches:

• Current Knowledge on Localization:

  • Immunofluorescent staining of human A549 cells has demonstrated QDPR localization to mitochondria

  • This mitochondrial association aligns with its metabolic function in BH4 regeneration

  • In brain tissue, QDPR shows strong cytoplasmic expression in glial cells

• Immunofluorescence Methodology:

  • Recommended fixation: Paraformaldehyde (PFA)

  • Permeabilization: Triton X-100 is effective for accessing intracellular QDPR

  • Antibody dilution: 0.25-2 μg/ml for immunofluorescence applications

• Co-localization Studies:

  • Combine QDPR antibodies with established markers for specific organelles:

    • Mitochondria: MitoTracker or antibodies against mitochondrial proteins

    • Endoplasmic reticulum: Calnexin or PDI

    • Cytosolic fraction: Tubulin or other cytoskeletal markers

• Advanced Microscopy Approaches:

  • Super-resolution microscopy can provide detailed visualization of QDPR's precise localization

  • Live-cell imaging with fluorescently tagged QDPR can reveal dynamic localization patterns

• Biochemical Fractionation:

  • Differential centrifugation followed by Western blotting can confirm QDPR enrichment in specific subcellular fractions

  • Compare results with immunofluorescence findings for comprehensive localization data

This combination of approaches provides complementary information about QDPR's subcellular distribution, which may vary between cell types and under different physiological conditions.

How does QDPR function in the tetrahydrobiopterin regeneration pathway and what are the implications for neurological disorders?

QDPR plays a central role in the BH4 regeneration pathway with significant implications for neurological function:

• Biochemical Pathway Context:

  • Tyrosine and tryptophan serve as precursors for serotonin and dopamine, respectively

  • Their conversion requires hydroxylases that absolutely depend on BH4 as a cofactor

  • During hydroxylation reactions, BH4 is oxidized to q-BH2 (quinonoid dihydrobiopterin)

  • QDPR regenerates BH4 from q-BH2, maintaining sufficient levels of this critical cofactor

• Experimental Models to Study QDPR Function:

  • QDPR knockout models demonstrate neurological phenotypes

  • Liver, kidney, and brain tissues from mouse models show high QDPR expression and are suitable for functional studies

  • Cell lines expressing hydroxylases can be used to study the impact of QDPR manipulation

• Relationship to Neurological Disorders:

  • Dysregulation of QDPR activity has been linked to various neurological disorders:

    • Parkinson's disease: Reduced BH4 affects dopamine synthesis

    • Depression: Impact on serotonin production pathways

    • Phenylketonuria type 2 (PKU2): Genetic QDPR deficiencies lead to hyperphenylalaninemia

• Therapeutic Implications:

  • QDPR represents a potential therapeutic target for neurological disorders

  • Understanding its structure-function relationship could guide pharmacological interventions

  • Antibodies serve as critical tools for validating therapeutic approaches targeting this pathway

This enzyme's central position in neurotransmitter synthesis pathways makes it a valuable target for both basic neuroscience research and translational studies of neurological disorders.

What strategies can researchers use to validate the specificity of QDPR antibodies?

Validation of QDPR antibody specificity requires a multi-faceted approach:

• Positive and Negative Controls:

  • Positive tissue controls: Mouse, rat, and human liver tissues consistently show high QDPR expression

  • Positive cell controls: Transfected 293T cells overexpressing QDPR

  • Negative controls: Non-transfected cell lysates, tissues from knockout models

• RNAi Validation:

  • QDPR Validated Chimera RNAi can effectively reduce endogenous QDPR expression

  • Compare antibody detection in control vs. RNAi-treated samples

  • Western blot analysis should show significant reduction in the 25-30 kDa QDPR band with GAPDH remaining unchanged as a loading control

• Cross-Reactivity Testing:

  • Test across multiple species (human, mouse, rat) to confirm expected cross-reactivity

  • Human QDPR shares 93% amino acid sequence identity with mouse QDPR

  • High conservation suggests antibodies should detect QDPR across these species

• Multiple Antibody Validation:

  • Compare results using antibodies from different sources or raised against different epitopes

  • Consistent results across multiple antibodies increase confidence in specificity

• Mass Spectrometry Confirmation:

  • Immunoprecipitate QDPR and confirm identity by mass spectrometry

  • This provides definitive identification of the protein being detected

These validation approaches should be documented and reported in research publications to ensure experimental rigor and reproducibility.

How can researchers troubleshoot common challenges with QDPR immunodetection?

Researchers may encounter several challenges when working with QDPR antibodies. Here are methodological solutions to common problems:

• Weak or Absent Signal in Western Blots:

  • Increase antibody concentration: Try 1:500 dilution if 1:2000 is ineffective

  • Enhance protein loading: QDPR is moderately abundant; use 30-50 μg total protein

  • Optimize transfer conditions: Use PVDF membrane for improved protein retention

  • Extend exposure time: QDPR may require longer detection periods

  • Verify tissue/cell source: Use liver tissue as a positive control with confirmed high expression

• Non-specific Bands:

  • Increase blocking stringency: Use 5% BSA or milk in TBST

  • Optimize antibody dilution: Too concentrated antibody may cause non-specific binding

  • Additional washing steps: Increase number and duration of washes

  • Use fresh antibody preparations: Degraded antibodies may cause non-specific binding

• Background in Immunohistochemistry:

  • Optimize antigen retrieval: Test both recommended methods (TE buffer pH 9.0 and citrate buffer pH 6.0)

  • Titrate primary antibody: Excessive concentration increases background

  • Use appropriate blocking: Include species-specific serum matching secondary antibody

  • Increase washing: Extend washing duration after both primary and secondary antibodies

• Inconsistent Results Across Experiments:

  • Standardize protocols: Document detailed protocols including buffer compositions

  • Use consistent controls: Include the same positive control in each experiment

  • Aliquot antibodies: Avoid repeated freeze-thaw cycles

  • Consider lot-to-lot variation: Test new lots against previous successful lots

These troubleshooting approaches address the most common technical challenges encountered when working with QDPR antibodies in various experimental applications.